Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.

Bamidele AO, Svingen PA, Sagstetter MR, Sarmento OF, Gonzalez M, Braga Neto MB, Kugathasan S, Lomberk G, Urrutia RA, Faubion WA Jr.

Cell Mol Gastroenterol Hepatol. 2018 Sep 14;7(1):55-71. doi: 10.1016/j.jcmgh.2018.08.009. eCollection 2019.


The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).

Sarmento OF, Svingen PA, Xiong Y, Sun Z, Bamidele AO, Mathison AJ, Smyrk TC, Nair AA, Gonzalez MM, Sagstetter MR, Baheti S, McGovern DP, Friton JJ, Papadakis KA, Gautam G, Xavier RJ, Urrutia RA, Faubion WA.

J Biol Chem. 2017 Jan 13;292(2):706-722. doi: 10.1074/jbc.M116.749663. Epub 2016 Dec 1.


A novel role for KLF14 in T regulatory cell differentiation.

Sarmento OF, Svingen PA, Xiong Y, Xavier RJ, McGovern D, Smyrk TC, Papadakis KA, Urrutia RA, Faubion WA.

Cell Mol Gastroenterol Hepatol. 2015 Mar 1;1(2):188-202.e4.


Stem cells for murine interstitial cells of cajal suppress cellular immunity and colitis via prostaglandin E2 secretion.

Dave M, Hayashi Y, Gajdos GB, Smyrk TC, Svingen PA, Kvasha SM, Lorincz A, Dong H, Faubion WA Jr, Ordog T.

Gastroenterology. 2015 May;148(5):978-90. doi: 10.1053/j.gastro.2015.01.036. Epub 2015 Jan 28.


Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene.

Xiong Y, Svingen PA, Sarmento OO, Smyrk TC, Dave M, Khanna S, Lomberk GA, Urrutia RA, Faubion WA Jr.

Am J Physiol Regul Integr Comp Physiol. 2014 Sep 15;307(6):R608-20. doi: 10.1152/ajpregu.00085.2014. Epub 2014 Jun 18.


Regulatory T cell kinetics in the peripheral blood of patients with Crohn's disease.

Rahman MK, Offord CP, Khanna S, Ford GC, Perrson XM, Svingen PA, Xiong Y, Bajzer Z, Faubion WA Jr.

Hum Immunol. 2013 Feb;74(2):145-50. doi: 10.1016/j.humimm.2012.10.021. Epub 2012 Nov 5.


Polycomb antagonizes p300/CREB-binding protein-associated factor to silence FOXP3 in a Kruppel-like factor-dependent manner.

Xiong Y, Khanna S, Grzenda AL, Sarmento OF, Svingen PA, Lomberk GA, Urrutia RA, Faubion WA Jr.

J Biol Chem. 2012 Oct 5;287(41):34372-85. doi: 10.1074/jbc.M111.325332. Epub 2012 Aug 15.


The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival.

Rahman MK, Midtling EH, Svingen PA, Xiong Y, Bell MP, Tung J, Smyrk T, Egan LJ, Faubion WA Jr.

J Immunol. 2010 Jun 15;184(12):7247-56. doi: 10.4049/jimmunol.0901479. Epub 2010 May 7.


FOXP3 regulates TLR10 expression in human T regulatory cells.

Bell MP, Svingen PA, Rahman MK, Xiong Y, Faubion WA Jr.

J Immunol. 2007 Aug 1;179(3):1893-900.


Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C.

Clin Cancer Res. 2005 Sep 15;11(18):6641-9.


Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.

Svingen PA, Loegering D, Rodriquez J, Meng XW, Mesner PW Jr, Holbeck S, Monks A, Krajewski S, Scudiero DA, Sausville EA, Reed JC, Lazebnik YA, Kaufmann SH.

Clin Cancer Res. 2004 Oct 15;10(20):6807-20.


Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines.

Kalli KR, Devine KE, Cabot MC, Arnt CR, Heldebrant MP, Svingen PA, Erlichman C, Hartmann LC, Conover CA, Kaufmann SH.

Mol Pharmacol. 2003 Dec;64(6):1434-43.


Immunoblot analysis and band depletion assays.

Kaufmann SH, Svingen PA.

Methods Mol Biol. 1999;94:253-68. No abstract available.


Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH.

Blood. 2002 Jan 15;99(2):664-71.


Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells.

Kottke TJ, Blajeski AL, Meng XW, Svingen PA, Ruchaud S, Mesner PW Jr, Boerner SA, Samejima K, Henriquez NV, Chilcote TJ, Lord J, Salmon M, Earnshaw WC, Kaufmann SH.

J Biol Chem. 2002 Jan 4;277(1):804-15. Epub 2001 Oct 24.


Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells.

Adams RR, Eckley DM, Vagnarelli P, Wheatley SP, Gerloff DL, Mackay AM, Svingen PA, Kaufmann SH, Earnshaw WC.

Chromosoma. 2001 May;110(2):65-74.


Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia.

Svingen PA, Karp JE, Krajewski S, Mesner PW Jr, Gore SD, Burke PJ, Reed JC, Lazebnik YA, Kaufmann SH.

Blood. 2000 Dec 1;96(12):3922-31.


Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c.

Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ.

J Clin Invest. 2000 Nov;106(9):1127-37.


Comparison of potential markers of farnesyltransferase inhibition.

Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH.

Clin Cancer Res. 2000 Jun;6(6):2318-25.


Flavopiridol binds to duplex DNA.

Bible KC, Bible RH Jr, Kottke TJ, Svingen PA, Xu K, Pang YP, Hajdu E, Kaufmann SH.

Cancer Res. 2000 May 1;60(9):2419-28.


A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH.

Cancer Res. 2000 Apr 1;60(7):1871-7.


Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity.

Budihardjo II, Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH.

Mol Pharmacol. 2000 Mar;57(3):529-38.


Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.

Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH.

Clin Cancer Res. 2000 Feb;6(2):681-92.


Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH.

Clin Cancer Res. 2000 Feb;6(2):661-70.


Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.

Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA, Kaufmann SH.

Clin Cancer Res. 2000 Jan;6(1):237-49.


Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent.

Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM.

Biochem Pharmacol. 1999 Sep 15;58(6):1057-66.


Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile.

Mesner PW Jr, Bible KC, Martins LM, Kottke TJ, Srinivasula SM, Svingen PA, Chilcote TJ, Basi GS, Tung JS, Krajewski S, Reed JC, Alnemri ES, Earnshaw WC, Kaufmann SH.

J Biol Chem. 1999 Aug 6;274(32):22635-45.


Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis.

Samejima K, Svingen PA, Basi GS, Kottke T, Mesner PW Jr, Stewart L, Durrieu F, Poirier GG, Alnemri ES, Champoux JJ, Kaufmann SH, Earnshaw WC.

J Biol Chem. 1999 Feb 12;274(7):4335-40.


Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.

Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH, Gores GJ.

J Clin Invest. 1999 Jan;103(1):137-45.


Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.

Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH.

Clin Cancer Res. 1998 Mar;4(3):683-91.


6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.

Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH.

Clin Cancer Res. 1998 Jan;4(1):117-30.


Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.

Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC.

Blood. 1998 Feb 1;91(3):991-1000.


Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis.

Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC, Kaufmann SH.

Blood. 1997 Dec 1;90(11):4283-96.


Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH.

Clin Cancer Res. 1997 May;3(5):761-70.


Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.

Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK.

Blood. 1997 Mar 15;89(6):2098-104.


Activation of multiple interleukin-1beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis.

Martins LM, Kottke T, Mesner PW, Basi GS, Sinha S, Frigon N Jr, Tatar E, Tung JS, Bryant K, Takahashi A, Svingen PA, Madden BJ, McCormick DJ, Earnshaw WC, Kaufmann SH.

J Biol Chem. 1997 Mar 14;272(11):7421-30.


Factors affecting topotecan sensitivity in human leukemia samples.

Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke T, Buckwalter CA, Jones RJ, Grochow LB, Burke PJ, Donehower RC, Rowinsky EK.

Ann N Y Acad Sci. 1996 Dec 13;803:128-42. Review. No abstract available.


Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK.

J Natl Cancer Inst. 1996 Jun 5;88(11):734-41.


Phase I trial of parenteral 6-thioguanine given on 5 consecutive days.

Kovach JS, Rubin J, Creagan ET, Schutt AJ, Kvols LK, Svingen PA, Hu TC.

Cancer Res. 1986 Nov;46(11):5959-62.


Enhancement of the antiproliferative activity of human interferon by polyamine depletion.

Kovach JS, Svingen PA.

Cancer Treat Rep. 1985 Jan;69(1):97-103.


Supplemental Content

Loading ...
Support Center